ARENTFOX SCHIFF LLP for HEMATECH INC
No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Consolidated Security, Disaster Assistance, and Continuing Appropriations Act, 2009 regarding FY '09 Department of Defense appropriations (Division C), FY '09 Labor/HHS/Education appropriations and FY '10 Department of Defense budget, all regarding advanced therapeutic development for bioterrorism response
Foreign entity interest: Kirin Pharma Company, Ltd., identified on the LD-1, is interested in the above-referenced lobbying activities that affect the commercial activities and overall business of its subsidiary Hematech, Inc.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARGO KLOSTERMAN | — |
| RACHEL G LATTIMORE | — |
| DAN RENBERG | — |
Medical/Disease Research/Clinical Labs MED
Funding for development of medical therapeutics for bioterrorism response
Foreign entity interest: Kirin Pharma Company, Ltd., identified on the LD-1, is interested in the above-referenced lobbying activities that affect the commercial activities and overall business of its subsidiary Hematech, Inc.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARGO KLOSTERMAN | — |
| RACHEL G LATTIMORE | — |
| DAN RENBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.